Myeloproliferative Neoplasms Clinical Trial

Clinical Trial Finder Myeloproliferative Neoplasms Trials

A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia

See Locations Near You

Summary

The purpose of this study is to find a dose of Nivolumab that can be safely added to Dasatinib in patients with leukemia-cml/" >Chronic Myeloid Leukemia.

View Eligibility Criteria

Eligibility Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.

Inclusion Criteria:

Confirmed diagnosis of Chronic Myeloid Leukemia in Chronic Phase or Accelerated Phase :

With historically documented Ph+ cells
≥2 prior Tyrosine Kinase Inhibitors (TKI) therapies for CML
Currently progressing, resistance to or with a suboptimal response to their most recent therapy
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score 0 - 1

Exclusion Criteria:

Blast phase CML
Known Abl-kinase mutation resistant to Dasatinib (e.g. T315I or T315A)

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT02011945

Recruitment Status:

Completed

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 21 Locations for this study

See Locations Near You

Winship Cancer Institute
Atlanta Georgia, 30322, United States
Dana Farber Cancer Institute.
Boston Massachusetts, 02215, United States
Ut Southwestern Medical Center At Dallas
Dallas Texas, 75390, United States
The University Of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Froedtert Hospital & Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States
Local Institution
St Leonards New South Wales, 2065, Australia
Local Institution
Adelaide South Australia, 5000, Australia
Local Institution
Parkville Victoria, 3050, Australia
QEII Health Sciences Centre-VG Site
Halifax Nova Scotia, B3H 2, Canada
Princess Margaret Cancer Centre
Toronto Ontario, M5G 2, Canada
Hopital Maisonneuve-Rosemont
Montreal Quebec, H1T 2, Canada
Local Institution
Bordeaux , 33000, France
Campus Virchow Klinikum Der Charite
Berlin , 13353, Germany
Universitaetsklinikum Bonn
Bonn , 53127, Germany
Universitaetsklinikum Carl Gustav Carus
Dresden , 01307, Germany
Universitaetsklinik Frankfurt
Frankfurt am Main , 60590, Germany
Local Institution
Napoli , 80131, Italy
Local Institution
Orbassano , 10043, Italy
Local Institution
Roma , 00161, Italy
Local Institution
Madrid , 28047, Spain
Local Institution
Valencia , 46010, Spain
Load More

How clear is this clinincal trial information?

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 1

Estimated Enrollment:

35

Study ID:

NCT02011945

Recruitment Status:

Completed

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider